Related Experiment Videos
Evidence for neuromelanin involvement in MPTP-induced neurotoxicity
Abstract:
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reproduces certain clinical, pathological, and neurochemical features of Parkinson's disease. MPTP is metabolized by monoamine oxidase Type B to 1-methyl-4-phenylpyridine (MPP+), which is selectively accumulated by high-affinity uptake mechanisms into dopaminergic neurons. Lyden et al. described low-affinity binding of MPTP to synthetic and retinal melanin. We showed that MPP+ binds to neuromelanin with high affinity, suggesting that in MPTP neurotoxicity, MPP+ enters nigral neurons by the dopamine uptake system and binds to neuromelanin, which serves as a depot, continuously releasing MPP+ until it destroys the cells. This model predicts that agents which compete with MPP+ binding to neuromelanin should partially protect the dopamine neurons from MPTP-induced toxicity. The most potent identified competitor for MPP+ binding to melanin is the antimalarial drug chloroquine, which has a high affinity for melanins. In the present study, chloroquine, administered to monkeys in conventional anti-malarial doses before MPTP, protects them from MPTP-induced parkinsonian motor abnormalities, dopamine depletion in the striatum, and neuropathological changes in the substantia nigra.
Insights
Chloroquine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by blocking 1-methyl-4-phenylpyridine (MPP+) binding to neuromelanin. This finding offers a potential therapeutic strategy for Parkinson's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure models Parkinson's disease.
- MPTP is metabolized to 1-methyl-4-phenylpyridine (MPP+), which targets dopaminergic neurons.
- MPP+ exhibits high-affinity binding to neuromelanin, acting as a neuronal depot.
Purpose of the Study:
- To investigate the neuroprotective potential of chloroquine against MPTP-induced toxicity.
- To determine if chloroquine, a melanin-binding agent, can prevent dopaminergic neuron damage.
Main Methods:
- MPP+ binding affinity to melanin was assessed.
- Chloroquine, a potent MPP+ competitor, was administered to MPTP-treated monkeys.
- Neuroprotection was evaluated by motor abnormalities, striatal dopamine levels, and substantia nigra pathology.
Main Results:
- Chloroquine demonstrated high affinity for melanin.
- Monkeys treated with chloroquine showed protection against MPTP-induced motor deficits.
- Dopamine depletion and neuropathological changes in the substantia nigra were reduced in chloroquine-treated subjects.
Conclusions:
- Chloroquine administration partially protects dopaminergic neurons from MPTP toxicity.
- This neuroprotection is attributed to chloroquine competing with MPP+ for neuromelanin binding.
- The findings support a model where melanin-binding agents can mitigate MPTP-induced parkinsonism.